BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, Lawendy N, Friedman GS, Quirk D, Su C, Reinisch W. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:116-125.e5. [PMID: 33039585 DOI: 10.1016/j.cgh.2020.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Neurath L, D'Amico F, Danese S. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. Expert Opin Emerg Drugs 2023;:1-16. [PMID: 36876333 DOI: 10.1080/14728214.2023.2186399] [Reference Citation Analysis]
2 Doktorova SA, Rafalskiy VV, Grabovetskaya YY, Korenev SV. JAK-inhibitors: clinical pharmacology and application perspectives. Rev Clin Pharm Drug Ther 2023;20:421-434. [DOI: 10.17816/rcf204421-434] [Reference Citation Analysis]
3 Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program. Patient 2023;16:95-103. [PMID: 36336750 DOI: 10.1007/s40271-022-00603-w] [Reference Citation Analysis]
4 Aslam N, Lo SW, Sikafi R, Barnes T, Segal J, Smith PJ, Limdi JK. A review of the therapeutic management of ulcerative colitis. Therap Adv Gastroenterol 2022;15:17562848221138160. [PMID: 36478780 DOI: 10.1177/17562848221138160] [Reference Citation Analysis]
5 Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panés J, Rubin DT. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis 2022:izac222. [PMID: 36242764 DOI: 10.1093/ibd/izac222] [Reference Citation Analysis]
6 Irving PM, Leung Y, Dubinsky MC. Review article: guide to tofacitinib dosing in patients with ulcerative colitis. Aliment Pharmacol Ther 2022;56:1131-45. [PMID: 35993338 DOI: 10.1111/apt.17185] [Reference Citation Analysis]
7 Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Rev Gastroenterol Hepatol 2022;16:737-52. [PMID: 35875997 DOI: 10.1080/17474124.2022.2106216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Winthrop KL, Vermeire S, Long MD, Panés J, Ng SC, Kulisek N, Mundayat R, Lawendy N, Vranic I, Modesto I, Su C, Melmed GY. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis 2023;29:85-96. [PMID: 35648151 DOI: 10.1093/ibd/izac063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Panaccione R, Abreu MT, Lazariciu I, Mundayat R, Lawendy N, Salese L, Woolcott JC, Sands BE, Chaparro M. Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open. Aliment Pharmacol Ther 2022;55:1534-44. [PMID: 35246988 DOI: 10.1111/apt.16848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 . Colitis ulcerosa: Tofacitinib als Langzeit-Erhaltungstherapie nach Remission. Z Gastroenterol 2022;60:284-284. [DOI: 10.1055/a-1740-1744] [Reference Citation Analysis]
11 Swei EC, Fox CM, Bowles DW, Rizeq MN, Onyiah JC. Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera. ACG Case Rep J 2022;9:e00741. [PMID: 35018293 DOI: 10.14309/crj.0000000000000741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Taxonera C, Carpio López D, Cabez Manas A, Hinojosa del Val JE. Clinical settings with tofacitinib in ulcerative colitis. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8660/2022] [Reference Citation Analysis]
13 D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2022;16:835-44. [PMID: 34791103 DOI: 10.1093/ecco-jcc/jjab206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
14 Knyazev OV, Kagramanova AV, Lishchinskaya AA, Li IA, Podolskaya DV, Shkurko TV, Nanaeva BA, Aleksandrov TL, Baranova TA, Tishaeva IA, Zvyaglova MY, Parfenov AI. Efficacy and safety of tofacitinib in moderate and severe ulcerative colitis in real clinical practice: three years of observation. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-15-20-29] [Reference Citation Analysis]